Affylmmune Therapeutics, a Natik MA-based clinical stage biotechnology company, raised $20M in Series A+ funding.
The round was led by ORI Capital (ORI). As part of the financing, Elaine Yang, Director at ORI Capital, will join the Board of Directors of AffyImmune.
The company intends to use the funds to advance the Phase 1 study of its lead asset, AIC1000, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer. In addition, AffyImmune will be able to conduct IND-enabling efforts for two additional pipeline candidates, and fund select drug discovery activities. The company also plans to double its headcount in the next nine months, with a focus on expanding its in-house discovery and leadership teams.
Led by Co-Founder & CEO Moonsoo Jin, Ph.D, and President & COO Eric von Hofe, Affylmmune Therapeutics provides cancer immunotherapy by extending the anti-cancer activity of CAR T cell therapy to solid tumors. Its “Tune & Track” platform tunes the affinity of CAR T cells to reduce toxicity and increase CAR T cell longevity while allowing in vivo monitoring through a proprietary tracking system.
FinSMEs
08/10/2021